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ABSTRACT 
Background: Takotsubo cardiomyopathy (TC) usually is not recognized until heart 
catheterization reveals typical wall motion abnormalities in the absence of significant 
coronary artery disease. It was our aim to identify TC by its unique cardiac biomarker 
profile at an early stage and, preferably, with non-invasive procedures only. 
Methods: Ratios of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 
and myoglobin, NT-proBNP and Troponin T (TnT), NT-proBNP and creatinekinase-
MB (CK-MB) were compared in patients with TC (n=39), patients with ST-elevation 
myocardial infarction (STEMI, n=48) and patients with non-ST-elevation myocardial 
infarction (NSTEMI, n=34). Biomarkers were recorded serially at admission and at 
the three consecutive days. Optimal cut-off values to distinguish TC from STEMI and 
NSTEMI were calculated with Receiver Operator Characteristic (ROC) - curves. 
Results: At admission a NT-proBNP (ng/l) / myoglobin (µg/l) ratio of 3.8, 
distinguished TC from STEMI (sensitivity: 89%, specificity: 90%), while a NT-proBNP 
(ng/l) / myoglobin (µg/l) ratio of 14 separated well between TC and NSTEMI 
(sensitivity: 65%, specificity: 90%). Best differentiation of TC and ACS was possible 
with the ratio of peak levels of NT-proBNP (ng/l) / TnT (µg/l). A cut-off value of NT-
proBNP (ng/l) / TnT (µg/l) ratio of 2889, distinguished TC from STEMI (sensitivity: 
91%, specificity: 95%), while a NT-proBNP (ng/l) / TnT (µg/l) ratio of 5000 separated 
well between TC and NSTEMI (sensitivity: 83%, specificity: 95%). 
Conclusions: TC goes along with a singular cardiac biomarker profile, which might 
be useful to identify patients with TC among patients presenting with acute coronary 
syndromes (ACS). 
 
Keywords: Acute coronary syndrome, takotsubo cardiomyopathy, NT-proBNP   
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Abbreviations list: 
AUC   Area under the curve 
CAD   Coronary artery disease 
IR   Interquartile range 
NSTEMI  Non-ST elevation myocardial infarction 
NT-proBNP  N-terminal prohormone of brain natriuretic peptide 
ROC   Receiver operator characteristic (curve) 
STEMI  ST-elevation myocardial infarction 
TC   Takotsubo cardiomyopathy  
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INTRODUCTION 
Takotsubo cardiomyopathy (TC), also known as stress induced 
cardiomyopathy or apical ballooning syndrome, was first described by Dote in 
1991.[1] It is defined as a fully reversible acute deterioration of left-ventricular 
function, which is mainly found in women after an episode of emotional or physical 
stress (e.g. psychosocial stress, sepsis, surgery).[2] TC is an important differential 
diagnosis of ST-elevation (STEMI) and Non-ST-elevation myocardial infarction 
(NSTEMI) and has an estimated incidence of 1 to 2 per cent or 7000 to 14000 
patients admitted to emergency departments in the U.S. for acute coronary 
syndromes.[2] As patients with TC – in contrast to those with STEMI or NSTEMI – 
have a favorable prognosis; diagnosis should be made early and preferably non-
invasively.[2] However, in the majority of patients TC is not recognized until cardiac 
catheterization reveals typical wall motion abnormalities in the absence of significant 
coronary artery disease. Consequently, diagnostic algorithms are needed to safely 
separate patients with acute myocardial ischemia, who qualify for an invasive 
treatment strategy, from those who do not, such as patients with TC. However, 
neither symptoms on admission, nor ECG changes are useful in the differentiation of 
TC from acute myocardial infarction.[3-5] Of note, troponin, creatinekinase (CK), CK-
MB and myoglobin levels are only slightly elevated in the majority of patients with 
TC.[6] In contrast, a pronounced increase in brain natriuretic peptide (BNP) is often 
seen in stress-induced cardiomyopathy.[7] 
We thought to elucidate whether TC can be identified among patients admitted 
for suspected acute coronary syndromes by its distinct cardiac biomarker profile only. 
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METHODS 
Patient population 
Patients with TC were compared to patients with STEMI or NSTEMI. STEMI 
and NSTEMI were defined according to the guidelines of the European Society of 
Cardiology.[8, 9] Patient data were retrospectively retrieved from our database (years 
2004 – 2009) and patients in the STEMI and NSTEMI group were matched for age 
and gender to those of the TC group. All patients underwent coronary angiography. 
Patients with known ischemic, dilative or valvular cardiomyopathy or severe renal 
insufficiency (defined as glomerular filtration rate < 30 ml/min at admission, 
calculated with the MDRD formula [10]) or paced cardiac rhythm were excluded.  
Glomerular filtration rate (GFR) was documented as “> 60 ml/min” or lower, as the 
MDRD formula can only be applied appropriately in the setting of a GFR lower than 
60 ml/min.  
Patients in the TC group had to meet the proposed Mayo Clinic criteria[2] for 
Takotsubo cardiomyopathy: 
• Transient hypokinesis, akinesis or dyskinesis of the left ventricular mid 
segments with or without apical involvement. The regional wall motion 
abnormalities typically extend beyond a single epicardial coronary distribution. 
A stressful trigger is often, but not always present. 
• Absence of obstructive coronary disease or angiographic evidence of acute 
plaque rupture. 
• New electrocardiographic abnormalities (either ST-segment elevation and/or T 
wave inversion) or modest elevation in cardiac troponin. 
• Absence of pheochromocytoma or myocarditis. 
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Electrocardiographic analysis 
ECGs obtained on arrival at the emergency department were analyzed by two 
physicians according to ESC guidelines.[11] 
 
Laboratory measurements 
Blood samples were taken every 8 hours during the first 24 hours after 
hospital admission, every 12 hours the following day and every 24 hours thereafter 
for, at least, 2 days. Time from onset of chest pain to drawing of the first blood 
sample was measured, as well as the period from onset of pain to the peak NT-
proBNP and TNT levels. Further, some commonly used markers of myocardial 
necrosis — CK and CK-MB — were measured. Myoglobin, representing one of the 
earliest markers of myocardial necrosis was measured at entry only. Peak CRP 
levels were recorded. Blood samples were analyzed using the cobas® analyzer 
(Roche Diagnostics, Basel, Switzerland) at the Institute of Clinical Chemistry of the 
University Hospital Zurich. 
 
Follow-up of Takotsubo patients 
Baseline and follow-up ejection fraction was assessed using echocardiography 
according to standard procedures.[12] Clinical follow-up was retrospectively obtained 
from our clinical database according to follow-up visits. 
 
Statistical analysis 
All statistical analyses were performed using SPSS 17.0 (SPSS Schweiz AG, 
Zurich, Switzerland). Continuous variables are presented as median with the 
interquartile range (25. – 75. percentile) in brackets. For evaluation of normal 
distribution the Kolmogorov-Smirnoff test was used. To identify significant differences 
between the TC, the STEMI and the NSTEMI groups, the Chi-square test was used 
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for categorical variables and the Kruskal-Wallis test for numerical variables. A two-
sided p-value of < 0.05 was considered significant. Receiver operator characteristic 
(ROC) - curves were drawn and optimal cut-off values are calculated. Confidence 
intervals are presented in brackets. 
 
Ethical statement 
The authors of this manuscript have certified that they comply with the 
Principles of Ethical Publishing in the International Journal of Cardiology according to 
Shewan and Coats.[13]  
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RESULTS 
Baseline characteristics 
39 patients with TC were identified. 48 matched patients were included in the 
STEMI group and 34 matched patients in the NSTEMI group. Baseline characteristics 
are summarized in Table 1. Only one TC patient presented without ECG changes. 
Six TC patients (15%) had dynamic ECG changes, 14 (36%) presented with ST-
segment elevation. Two patients had giant negative T-waves, 3 patients had ST-
segment depression, 12 patients (32%) had T-inversion and one patient presented 
with new onset of left bundle branch block. Ejection fraction at baseline was 
significantly lower in the TC group (45%) compared to the STEMI (49%, p=0.02) and 
NSTEMI (55%, p<0.001) group. In the TC group 12 (32%) events were preceded by 
unusual emotional stress, 8 (21%) events happened after physical stress or surgery. 
In ten patients (27%), no trigger could be identified (detailed information is shown in 
Table 2). Patients with TC were treated in hospital for 4 days (IR: 3 – 6 days; Table 
2). In the TC group ejection fraction at baseline was 45% (IR: 40 – 50%) and 
increased significantly during follow-up to 65% (IR: 60 - 67; p<0.0001). 
 
Biomarkers 
TnT, CK, CK-MB and myoglobin were only slightly elevated in the TC study 
population compared to the other two groups (Table 3 and Figure 1). Peak C-
reactive protein (CRP) values did not significantly different between the study groups 
and were 20 mg/l (6 – 58.3 mg/l) in the TC group, 29 mg/l (13 – 108 mg/l) in the 
STEMI group and 18 mg/l (6 – 37.5 mg/l) in the NSTEMI group. 
 
Cardiac biomarker ratios 
At admission a cut-off value of NT-proBNP (ng/l) / myoglobin (µg/l) ratio of 3.8, 
distinguished TC from STEMI with a sensitivity of 89% and specificity of 90%, while a 
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NT-proBNP (ng/l) / myoglobin (µg/l) ratio of 14 separated well between TC and 
NSTEMI with a sensitivity of 65% and a specificity of 90%, respectively (Table 4). 
Best differentiation of TC and ACS was possible with the ratio of peak levels of 
NT-proBNP (ng/l) / TnT (µg/l). A cut-off value of NT-proBNP (ng/l) / TnT (µg/l) ratio of 
2889, distinguished TC from STEMI with a sensitivity of 91% and specificity of 95%, 
while a NT-proBNP (ng/l) / TnT (µg/l) ratio of 5000 separated well between TC and 
NSTEMI with a sensitivity of 83% and a specificity of 95%, respectively (Table 4). 
 
In-hospital mortality 
Two patients died in the TC group: One died from hypoxic encephalopathy 
after prolonged resuscitation, one died from sepsis and renal failure. Within the 
STEMI group five patients died. Two died from hypoxic encephalopathy after 
prolonged resuscitation and three patients from cardiogenic shock. In the NSTEMI 
group two patients died. One died due to arrhythmia and cardiogenic shock the other 
patient died from hypoxic encephalopathy after resuscitation. There was no 
significant difference in overall mortality between the three study groups. 
 
Follow-up 
The patients in the TC group had a median follow-up of 33 months (IR: 12 – 
44 months). Six patients were lost to follow-up. Three (8%) of the 39 TC patients 
experienced recurrent episodes (Table 2). In these 3 TC patients normalization of 
ejection fraction after their first Takotsubo event had been documented by 
echocardiography. The event-free period varied widely from 14 months up to six 
years. In one female patient generalized tonic-clonic seizure was the cause of two 
Takotsubo events. In a second female patient, the trigger of the first Takotsubo event 
was prior pulmonary surgery, while the second event was heralded by respiratory 
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failure due to chronic obstructive lung disease. In one male patient no certain 
triggering event could be identified neither for the first nor second episode of TC. 
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DISCUSSION 
This study demonstrates that in patients with Takotsubo cardiomyopathy a 
unique NT-proBNP / myoglobin or NT-proBNP / TnT ratio provides additional 
diagnostic information for an early and, potentially, non-invasive diagnosis of TC with 
a high sensitivity and specificity. 
Our observations go along with findings of Madhavan et al., who evaluated the 
neurohumoral and cardiac biomarker profile in patients with TC and compared it to 
patients with ST-elevation myocardial infarction.[7] They could demonstrate that 
patients with STEMI had lower BNP levels and greater elevations of troponin T and 
CK-MB, compared to the TC group. Takotsubo cardiomyopathy could be 
distinguished from STEMI by calculating the BNP / peak troponin T ratio with a 
sensitivity of 94% and a specificity of 100%.[7] However, their study had several 
limitations: First, BNP was measured only once on day one or two, and second TnT 
levels were assessed upon admission and once a day thereafter. Additionally, the 
sample size was small with only 19 TC patients and 10 patients with STEMI, while 
patients with NSTEMI were not included.[7] 
It was therefore the object of our study to delineate a unique biomarker profile 
reflecting Takotsubo cardiomyopathy that would be commonly available and reliable 
enough to distinguish patients with stress-induced cardiomyopathy from those with 
STEMI or NSTEMI. 
To investigate, whether the ratio of cardiac biomarkers is of diagnostic value, 
we retrospectively analyzed the ratio of NT-proBNP and several cardiac biomarkers 
in patients with TC, STEMI or NSTEMI: The NT-proBNP / myoglobin ratio at 
admission might be of use in the emergency department setting, as it emerged as the 
earliest marker to identify patients with TC. However, NT-proBNP / myoglobin ratio 
has a sensitivity of 89% at a specificity of 90% for discrimination of TC from STEMI 
and a sensitivity of 65% at a specificity of 90% to distinguish TC from NSTEMI. In this 
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context, it is important to be aware that myoglobin levels will peak approximately two 
to six hours after onset of pain.[14, 15] 
Of note, to distinguish acute coronary syndromes from Takotsubo at the 
highest specificity and sensitivity, the use of the peak NT-proBNP / peak TnT ratio 
appeared most accurate. However, in our study population NT-proBNP levels usually 
peaked 22 – 26 hours after a cardiac event, whereas TnT levels peak 8 to 13 hours 
after the first manifestation of chest pain. This delay is, for sure, not acceptable in the 
acute setting, but in many cases the patients are admitted to the emergency 
department >24 hours after the onset of pain. Further, the NT-proBNP / TnT peak 
level ratio has an additional diagnostic value to predict the evolution of left-ventricular 
function even before hospital discharge of the patient, as TC usually goes along with 
a favorable prognosis. The NT-proBNP peak / CK-MB peak ratio revealed a 
comparable specificity and sensitivity. Contrarily, NT-proBNP / CK-MB ratios 
obtained at admission, at day 1 and 2 proved to be inferior to the other biomarker 
ratios and should be omitted. 
The mechanism of NT-proBNP release is very similar in TC and ACS, as NT-
proBNP secretion is mainly provoked by myocardial stretch, caused by pump 
failure.[16] In contrast, markers of myocardial damage – like troponin, CK, CK-MB 
and myoglobin – will especially be elevated in the setting of membrane leakage 
caused by myocardial necrosis, whereas TC is characterized by reversible 
myocardial damage without necrosis.[17-19] Therefore, the typical constellation of TC 
is characterized by a steep increase of NT-proBNP due to the compromised left 
ventricular function in the presence of only slightly elevated markers of myocardial 
necrosis. 
Larson et al. observed in 1335 patients who were referred to the emergency 
department for suspected STEMI, that a proportion of 1.1% of patients finally had TC 
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as the underlying condition.[20] Hence, cardiac catheterization was unnecessary in 
these patients. 
We clearly state, that in patients who present with acute onset of typical chest 
pain and ST-elevation on ECG, immediate coronary angiography is warranted. 
Moreover, coronary artery disease will have to be excluded in all patients with 
suspected ACS. However, in hemodynamically stable patients presenting > 12 hours 
after onset of pain, non-invasive imaging methods might be preferred, if cardiac 
biomarker ratios suggest the presence of TC. In these patients, 64-slice multidetector 
computed tomography could be a suitable diagnostic tool to confirm the diagnosis of 
TC.[21-23] 
 
Limitations 
This study is retrospective in nature and reports on a small study population. 
However, due to the low frequency of the disease, in 14 comparable studies, the 
mean number of patients with TC was 20 (range: 9 to 88) compared to 39 in this 
study.[24] 
Troponin and NT-proBNP assays might vary among different manufactures, 
which may lead to differing cut-off values. 
 
CONCLUSION 
Patients with Takotsubo cardiomyopathy exhibit a typical cardiac biomarker 
profile, which might serve as an additional tool to distinguish these patients from 
those with STEMI or NSTEMI at an early stage. Nevertheless, obstructive coronary 
artery disease has to be ruled out in any case, but preferably, with non-invasive 
imaging modalities. 
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Table 1: Baseline characteristics of the three study groups. 
 
 Takotsubo (n=39) STEMI (n=48) NSTEMI (n=34) p-value 
Age (years) 71 (57 – 77) 64.5 (53.3 – 73) 69 (57.8 – 77) 0.14 
Female (n, %) 35 (90) 42 (88) 30 (88) 0.95 
Body-Mass-Index (kg/m2) 25.1 (22.1 – 26.8) 24.6 (22.6 – 27.1) 26 (23.7 – 29.3) 0.2 
Symptoms at admission (n, %)    0.12 
 Typical chest pain 30 (77) 44 (92) 31 (91)  
 Resuscitation 2 (5) 4 (8) 2 (6)  
 Syncope 5 (13) 0 1 (3)   
 Dyspnoe 1 (3) 0 0  
Time to hospital admission 
(hours) 7.5 (5.3 – 12.8) 6 (4 – 10) 10 (6.8 – 13.3) 0.13 
Glomerular filtration rate 
(MDRD formula ml/min) 60 (60 – 60) 60 (55 – 60) 60 (60 – 60) 0.08 
Hypertension (n, %) 24 (62) 24 (50) 22 (65) 0.23 
Diabetes (n, %)    0.48 
 Non-insulin dependent 3 (8) 4 (8) 5 (15)  
 Insulin dependent 1 (3) 1 (2) 0  
 Diet only 0 4 (8) 2 (6)  
Smoker (n, %)    0.57 
 Current 10 (26) 16 (33) 10 (29)  
 Former 5 (13) 5 (10) 1 (3)  
Hyperlipidemia (n, %) 13 (33) 24 (50) 14 (41) 0.22 
Family history of CAD (n, %) 6 (15) 17 (35) 9 (27) 0.1 
Culprit lesion (n, %)     
 LAD  25 (52) 11 (32)  
 RCX  6 (12.5) 12 (35)  
 RCA  16 (33) 10 (29)  
 Main stem  1 (2) 1 (3)  
LVEDP (mmHg) 22.5 (15 – 29) 25.0 (17.0 – 29.0) 19 (14.3 – 24.8) 0.31 
Ejection fraction - baseline (%) 45 (40 – 50)  49 (42 – 60) 55 (49 – 60) <0.001 
 
Continuous variables are presented as median with interquartile range in brackets. 
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Table 2. Characteristic parameters of the Takotsubo study population. 
 
 Takotsubo (n=39) 
Type of Takotsubo  
 Apical ballooning 29 (74) 
 Midventricular 9 (23) 
 Lateral/apical 1 (3) 
Ejection fraction - baseline (%) 45 (40 – 50) 
Ejection fraction - follow-up (%) 65 (60 – 67) 
Echo follow-up (months) 3 (1.0 – 11.3) 
Clinical follow-up (months) 33 (12 – 44) 
Hospitalization (days) 4 (3 – 6) 
Trigger of Takotsubo event (n, %)  
 Seizure 2 (5) 
 Death of relative 1 (3) 
 Psychosomatic 3 (8) 
 Stress in family 8 (21) 
 Syncope 3 (8) 
 Alcohol abstinence 2 (5) 
 Surgery 5 (13) 
 Physical stress 3 (8) 
 Unclear 10 (27) 
 Accident 2 (5) 
Recurrent Takotsubo episode during clinical 
follow-up period (n, %) 3 (8) 
3-years estimator of freedom from death or 
recurrent Takotsubo episodes (%) 84 ± 7.5 
 
Continuous variables are presented as median with interquartile range in brackets.  
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Table 3: Time course of cardiac biomarkers in the three study groups. 
 
 Takotsubo (n=39) STEMI (n=48) NSTEMI (n=34) p-value 
TnT at admission (µg/l) 0.34 (0.15 – 0.61) 2.55 (0.35 – 6.91) 1.02 (0.40 – 3.37) <0.001 
Myoglobin at admission 85.0 (46.0 – 167) 729 (359 – 2234) 506 (134 – 1032) <0.001 
TnT at day 1 (µg/l) 0.44 (0.20 – 0.68) 6.5 (2.58 – 9.46) 3.33 (1.24 – 6.35) <0.001 
TnT at day 2 (µg/l) 0.19 (0.09 – 0.37) 3.9 (2.63 – 6.27) 1.63 (1.03 – 3.25) <0.001 
CK-MB at day 1 (U/l) 36.0 (22.0 – 48.0) 258 (107 – 395) 137 (71.0 – 242) <0.001 
CK-MB at day 2 (U/l) 18.5 (15.0 – 26.3) 155 (83.5 – 253) 115 (58.0 – 197) <0.001 
CK at day 1 (U/l) 145 (92.5 – 239) 2006 (1251 – 3951) 1364 (615 –1751) <0.001 
CK at day 2 (U/l) 133 (75 – 161) 1402 (969 – 2169) 1094 (365 – 1689) <0.001 
NT-proBNP level at admission (ng/l) 1723 (754 – 5699) 461 (188 – 1451) 977 (499 – 2290) 0.001 
NT-proBNP at day 1 (ng/l) 2164 (741 – 6999) 1231 (431 – 2579) 1375 (873 – 2465) 0.13 
NT-proBNP at day 2 (ng/l) 6112 (2992 – 8153) 2549 (1691 – 5661) 1991 (996 – 4248) 0.006 
 
Continuous variables are presented as median with interquartile range in brackets. 
 
Page 21 of 22 
Table 4: Cut-off values with corresponding specificity and sensitivity. 
 
Cut-off values for differentiation of Takotsubo and STEMI     
 Cut-off specificity 95% Specificity 95% Area under the curve 95% confidence interval 
NT-proBNP (ng/l) / myoglobin (µg/l) at admission 12 sensitivity: 65% 0.951 0.899 – 1.000 
peak NT-proBNP (ng/l) / peak TnT (µg/l) 2889 sensitivity: 91% 0.980 0.783 – 0.984 
peak NT-proBNP (ng/l) / peak CK-MB (µg/l) 42 sensitivity: 86% 0.968 0.813 – 0.976 
     
Cut-off values for differentiation of Takotsubo and NSTEMI     
 Cut-off specificity 95% Specificity 95% Area under the curve 95% confidence interval 
NT-proBNP (ng/l) / myoglobin (µg/l) at admission 17 sensitivity: 58% 0.840 0.735 – 0.948 
peak NT-proBNP (ng/l) / peak TnT (µg/l) 5000 sensitivity: 83% 0.977 0.698 – 0.953 
peak NT-proBNP (ng/l) / peak CK-MB (µg/l) 78 sensitivity: 82% 0.955 0.579 – 0.942 
 
 
Page 22 of 22 
 
Figure 1: Time course of different cardiac biomarkers over a three days time frame 
after an event. (see also corresponding Table 3.) 
 
